Noparatayaporn Prapaporn, Thavorncharoensap Montarat, Chaikledkaew Usa, Looareesuwan Panu, Shantavasinkul Prapimporn Chattranukulchai, Sumritpradit Preeda, Thakkinstian Ammarin
Mahidol University Health Technology Assessment (MUHTA) Graduate Program, Bangkok, Thailand.
Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand.
PLoS One. 2024 Dec 10;19(12):e0315336. doi: 10.1371/journal.pone.0315336. eCollection 2024.
Bariatric surgery is another treatment options for patients with obesity, who cannot achieve weight controlled by conservative non-surgical therapy. Although bariatric surgery provides clinical benefits for these patients, it is costly. This study aims to evaluate the cost-effectiveness of bariatric surgery, as compared to nonbariatric surgery, in patients with body mass index (BMI) ≥32.5 kg/m2 and type 2 diabetes mellitus (T2DM), and to estimate the budget impact of bariatric surgery in Thailand.
A Markov model was developed to estimate and compare total costs incurred and quality-adjusted life years (QALYs) gained between bariatric surgery and nonbariatric surgery over lifetime horizontal. Analysis was conducted under payer and societal perspectives. Costs and outcomes were discounted at an annual rate of 3%. The outcomes were presented as incremental cost- effectiveness ratio (ICER).
Under payer's perspective, bariatric surgery resulted in higher total lifetime cost (676,658.39 baht vs 574,683.38 baht) and QALYs gained (16.08 QALYs vs 14.78 QALYs), as compared to nonbariatric surgery, resulting in an ICER of 78,643.02 baht/QALY. Similarly, under the societal perspective, bariatric surgery resulted in higher total lifetime cost (1,451,923.83 baht vs 1,407,590.49 baht) and QALYs gained (16.08 QALYs vs 14.78 QALYs), as compared to nonbariatric surgery. Under societal perspective, ICER was estimated at 34,189.82 baht/QALY. A 5-year budget impact analysis indicated that bariatric surgery incurred the total budget of 223,821 million baht.
At the cost-effectiveness threshold of 160,000 baht/QALY, bariatric surgery was a cost-effective strategy and should continue to be included in the benefit package for patients with obesity and T2DM.
减重手术是肥胖患者的另一种治疗选择,这些患者无法通过保守的非手术疗法控制体重。尽管减重手术为这些患者带来了临床益处,但成本高昂。本研究旨在评估与非减重手术相比,体重指数(BMI)≥32.5 kg/m²且患有2型糖尿病(T2DM)的患者接受减重手术的成本效益,并估算减重手术对泰国的预算影响。
建立马尔可夫模型,以估计和比较减重手术和非减重手术在终身水平上产生的总成本以及获得的质量调整生命年(QALY)。从支付方和社会角度进行分析。成本和结果按3%的年利率进行贴现。结果以增量成本效益比(ICER)表示。
从支付方角度来看,与非减重手术相比,减重手术导致更高的终身总成本(676,658.39泰铢对574,683.38泰铢)和获得的QALY(16.08个QALY对14.78个QALY),ICER为78,643.02泰铢/QALY。同样,从社会角度来看,与非减重手术相比,减重手术导致更高的终身总成本(1,451,923.83泰铢对1,407,590.49泰铢)和获得的QALY(16.08个QALY对14.78个QALY)。从社会角度来看,ICER估计为3,4189.82泰铢/QALY。一项为期5年的预算影响分析表明,减重手术的总预算为2238.21亿泰铢。
在成本效益阈值为160,000泰铢/QALY时,减重手术是一种具有成本效益的策略,应继续纳入肥胖和T2DM患者的福利套餐中。